Recently, the domestic substitute Travoprost ophthalmic solution (product name: Nomin) which was independently developed by Grand Pharmaceutical (China) Co., Ltd. and is used to treat glaucoma, was officially granted market approval by the State Administration for Market Regulation. This breaks up the existing market monopoly and takes an early market share advantage in the market for glaucoma drugs.

As China’s first domestic generic Travoprost, the successful approval of Nomin enriches Grand Medicine’s ophthalmic medicine and marks a significant breakthrough in the treatment and R&D of glaucoma in China. According to expert analysis, the Travoprost ophthalmic solution was a type of medicine originally developed by Alcon in March 2001, marketed under the brand name Travatan. Since its entry into the Chinese market in 2004, Travatan has long monopolized the sector of clinical medicines for glaucoma treatment. The approval of Grand Medicine’s Nomin breaks up this monopoly, as previously there were no other similar products on the market.

WHO reports indicate that in recent years, the number of glaucoma patients is increasing both in China and abroad. It is estimated that by 2020, glaucoma patients around the world will total 80 million and glaucoma patients in China will total 22 million. The glaucoma morbidity rate in people over 40 is 2.3%. There is huge domestic demand for this product and Nomin has been recognized by industrial experts. It is regarded as the first choice in glaucoma treatment.

As a modern comprehensive medicine group, Grand Medicine’s ophthalmic medical products are an important core business. The R&D breakthroughs of Nomin are also a representation of the significant results of the product innovation and quality upgrading seen at Grand Medicine. This successful approval will further enhance the core competitiveness of Grand Medicine in the field of ophthalmology and provide market support for other in-research products designed to treat glaucoma, guaranteeing the long-term development of Grand Medicine.